Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

The emergence of various novel therapies over the last decade has changed the therapeutic
landscape for multiple myeloma. While the clinical outcomes have improved significantly …

PURPOSE The anti–B-cell maturation antigen BiTE molecule AMG 420 was assessed in
patients with relapsed/refractory multiple myeloma. PATIENTS AND METHODS In this first-in …

Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-
cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic …

B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due
to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted …

Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-
cell therapy have not been well studied. In an analysis of 83 patients with hematologic …

Despite a substantial survival improvement and the availability of many new drugs in the last
2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic …

The development of chimeric antigen receptor (CAR) T‐cell therapy for select hematological
malignancies represents one of the most remarkable therapeutic advances in the past …

In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that
have revolutionized the landscape of care for cancer patients. While traditional pillars such …

Despite considerable advances in treatment approaches in the past two decades, multiple
myeloma remains an incurable disease. Treatments for myeloma continue to evolve with …